根据最终合并协议,Viewpoint的每一股已发行和流通股份将转换为获得Isoray 3.3212股的权利。Viewpoint股东将拥有Isoray完全稀释的流通股49%的股份。
$华海药业(SH600521)$ $华东医药(SZ000963...查看全文
$IsoRay, Inc.(ISR)$ CT ORDER - Confidential treatment order Filed: 2017-11-27 AccNo: 9999999997-17-010030 Size: 16 KB 网页链接
$IsoRay, Inc.(ISR)$ 内部交易: 2017-11-24,Controller/Prin Fin&Acct Offic,Austin Mark John ,买入,2040普通股, $0.49
$IsoRay, Inc.(ISR)$ 内部交易: 2017-11-22,Controller/Prin Fin&Acct Offic,Austin Mark John ,买入,1825普通股, $0.49
$IsoRay, Inc.(ISR)$ 内部交易: 2017-11-21,Controller/Prin Fin&Acct Offic,Austin Mark John ,买入,5400普通股, $0.48
$IsoRay, Inc.(ISR)$ 内部交易: 2017-11-20,VP of Sales & Marketing,Krachon Michael ,买入,55000普通股, $0.50
$IsoRay, Inc.(ISR)$ 内部交易: 2017-11-20,CEO and 董事会主席,LAVOY THOMAS C ,期权,82810普通股, $0.61
$IsoRay, Inc.(ISR)$ 内部交易: 2017-11-16,Director,Vitale Philip J ,买入,30000普通股, $0.44
$IsoRay, Inc.(ISR)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-11-14 AccNo: 0001437749-17-019383 Size: 2 MB 网页链接
$IsoRay, Inc.(ISR)$ 8-K - Current report Filed: 2017-11-14 AccNo: 0001437749-17-019349 Size: 159 KBItem 2.02: Results of Operations and Financial ConditionItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$IsoRay, Inc.(ISR)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-11-03 AccNo: 0001437749-17-018280 Size: 414 KB 网页链接